Department of Endocrinology and Metabolism, Pituitary Research Center, Kocaeli University Faculty of Medicine, Kocaeli, Turkey.
Department of Pathology, Kocaeli University Faculty of Medicine, Kocaeli, Turkey.
Endocrine. 2023 Dec;82(3):622-630. doi: 10.1007/s12020-023-03480-x. Epub 2023 Aug 10.
This study aims to analyze the clinicopathological features, diagnostic steps, and therapeutic results of TSHomas and to reveal the effective factors on remission.
The clinical, radiological, and pathological features and surgical and endocrinological results of 41 TSHoma cases followed between 2005 and 2022 were retrospectively analyzed. The factors affecting the surgical cure were investigated by comparing the groups with and without remission.
A total of 41 patients (23 male,18 female) were included in the study and the mean age was 42 (31.5-49). Palpitation and headache were the most common complaints. The time from the onset of symptoms to diagnosis was 8 (3-20) months. There were 8 patients with a preoperative clinical and biochemical diagnosis of TSH + GH co-secretion. In the TRH stimulation test, a blunted TSH response was obtained in 18 patients (90.0%). Complete suppression could not be obtained in any of the patients who underwent the T3 suppression test. The median maximum tumor diameter was 19.0 mm (6.8-41). There was microadenoma in 4 (9.8%) patients and macroadenoma in 37 patients (92.8%). Remission was achieved in 31 (75.6%) of 40 patients who underwent endoscopic transsphenoidal surgery (eTSS). The Ki-67 labeling index was 2% (1.00-4.00) in the entire patient group. Preoperative use of antithyroid drugs appears to be significantly associated with surgical cure.
Diagnosis of TSHoma is still full of challenges and dynamic tests remain important. Recognition and good management of inappropriate TSH secretion states affect subsequent surgical outcomes.
本研究旨在分析 TSH 瘤的临床病理特征、诊断步骤和治疗结果,并揭示缓解的有效因素。
回顾性分析 2005 年至 2022 年间随访的 41 例 TSH 瘤患者的临床、影像学和病理学特征以及手术和内分泌学结果。通过比较缓解组和未缓解组,探讨影响手术治愈的因素。
共纳入 41 例患者(23 例男性,18 例女性),平均年龄为 42(31.5-49)岁。心悸和头痛是最常见的症状。从症状出现到诊断的时间为 8(3-20)个月。有 8 例患者术前临床和生化诊断为 TSH+GH 共分泌。在 TRH 刺激试验中,18 例患者(90.0%)获得 TSH 反应迟钝。任何接受 T3 抑制试验的患者均无法完全抑制 TSH。最大肿瘤直径中位数为 19.0mm(6.8-41)。4 例(9.8%)患者为微腺瘤,37 例(92.8%)为大腺瘤。40 例行内镜经蝶窦手术(eTSS)的患者中,31 例(75.6%)达到缓解。整个患者组的 Ki-67 标记指数为 2%(1.00-4.00)。术前使用抗甲状腺药物似乎与手术治愈显著相关。
TSH 瘤的诊断仍然充满挑战,动态试验仍然很重要。识别和良好管理不适当的 TSH 分泌状态会影响后续的手术结果。